Vanguard Group's Updated Ownership in Kiniksa Pharmaceuticals

The Vanguard Group has filed an amendment to its Schedule 13G, reporting its updated ownership in Kiniksa Pharmaceuticals International Plc. As of September 30, 2025, Vanguard holds 3,063,135 shares, representing 7.04% of the company's common stock. This marks a decrease of 68,467 shares from its previous filing. The shares are held on behalf of Vanguard's clients, including investment companies and managed accounts. Vanguard certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.